WO2001039762A3 - Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system - Google Patents

Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system Download PDF

Info

Publication number
WO2001039762A3
WO2001039762A3 PCT/US2000/033103 US0033103W WO0139762A3 WO 2001039762 A3 WO2001039762 A3 WO 2001039762A3 US 0033103 W US0033103 W US 0033103W WO 0139762 A3 WO0139762 A3 WO 0139762A3
Authority
WO
WIPO (PCT)
Prior art keywords
taurultam
taurolidine
tumors
medicament
manufacture
Prior art date
Application number
PCT/US2000/033103
Other languages
French (fr)
Other versions
WO2001039762A2 (en
Inventor
Paul Calabresi
James Darnowski
Original Assignee
Rhode Island Hosp Lifespan Ptr
Paul Calabresi
James Darnowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27389609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001039762(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhode Island Hosp Lifespan Ptr, Paul Calabresi, James Darnowski filed Critical Rhode Island Hosp Lifespan Ptr
Priority to JP2001541495A priority Critical patent/JP5027369B2/en
Priority to AU20649/01A priority patent/AU784539B2/en
Priority to DE60030770T priority patent/DE60030770T2/en
Priority to CA2393159A priority patent/CA2393159C/en
Priority to EP00983965A priority patent/EP1246617B1/en
Publication of WO2001039762A2 publication Critical patent/WO2001039762A2/en
Publication of WO2001039762A3 publication Critical patent/WO2001039762A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.
PCT/US2000/033103 1999-12-06 2000-12-06 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system WO2001039762A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001541495A JP5027369B2 (en) 1999-12-06 2000-12-06 How to treat a tumor
AU20649/01A AU784539B2 (en) 1999-12-06 2000-12-06 Methods of treating tumors
DE60030770T DE60030770T2 (en) 1999-12-06 2000-12-06 USE OF TAUROLIDINE OR TAURULTAM FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF OVARIAN CARCINOMES
CA2393159A CA2393159C (en) 1999-12-06 2000-12-06 Methods of treating tumors
EP00983965A EP1246617B1 (en) 1999-12-06 2000-12-06 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US16912899P 1999-12-06 1999-12-06
US16912799P 1999-12-06 1999-12-06
US16912299P 1999-12-06 1999-12-06
US60/169,127 1999-12-06
US60/169,122 1999-12-06
US60/169,128 1999-12-06

Publications (2)

Publication Number Publication Date
WO2001039762A2 WO2001039762A2 (en) 2001-06-07
WO2001039762A3 true WO2001039762A3 (en) 2002-05-02

Family

ID=27389609

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/033104 WO2001039763A2 (en) 1999-12-06 2000-12-06 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
PCT/US2000/033103 WO2001039762A2 (en) 1999-12-06 2000-12-06 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2000/033104 WO2001039763A2 (en) 1999-12-06 2000-12-06 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors

Country Status (9)

Country Link
US (6) US6429224B1 (en)
EP (3) EP1246617B1 (en)
JP (5) JP5027369B2 (en)
AT (1) ATE339207T1 (en)
AU (2) AU784539B2 (en)
CA (3) CA2393159C (en)
DE (1) DE60030770T2 (en)
ES (2) ES2531547T3 (en)
WO (2) WO2001039763A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US8394397B2 (en) 2003-03-28 2013-03-12 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Adhesive antineoplastic compositions

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US20030027818A1 (en) 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
EP1797884B1 (en) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidine or taurultam for use in the treatment of tumors of the prostate, colon, lung and for the treatment of recurrent glioblastoma multiforme
CN100519525C (en) * 1999-12-06 2009-07-29 葛兰素集团有限公司 Aromatic sulfones and their medical use
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU779362B2 (en) 2000-10-27 2005-01-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
GB0104383D0 (en) * 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
AU2002252338B2 (en) * 2001-03-15 2007-09-13 Rhode Island Hospital, A Lifespan Partner Taurine compounds
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
AU2002362459B2 (en) * 2001-10-01 2007-08-02 Geistlich Pharma Ag Methods of inhibiting metastases
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
DE60306828T2 (en) * 2002-03-21 2007-08-02 Ed. Geistlich Söhne AG für chemische Industrie, Wolhusen Device for treating a tumor in the central nervous system
CN100372535C (en) * 2002-09-24 2008-03-05 诺瓦提斯公司 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US20050008684A1 (en) * 2003-07-10 2005-01-13 Claus Herdeis Method of treatment for acne, rosacea and ulcers with taurolidine and/or taurultam in a pharmaceutical composition
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
JP2007537200A (en) * 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ Taurolidine formulation and administration: therapeutic treatment and antibacterial protection against bacterial microfilm formation
AU2005265027A1 (en) * 2004-06-18 2006-01-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
US9220756B2 (en) * 2005-07-19 2015-12-29 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
WO2007077528A1 (en) * 2006-01-06 2007-07-12 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
US20100291173A1 (en) * 2006-09-05 2010-11-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of improving renal function
CA2661389C (en) * 2006-09-07 2016-04-12 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treating bone cancer
US20100316655A1 (en) * 2008-02-11 2010-12-16 Hall Matthew D Compounds with mdr1-inverse activity
DE102010010360A1 (en) * 2010-03-05 2011-09-08 Gamptec Gmbh Taurolidine formulations and process for its preparation
AU2011262308B2 (en) * 2010-06-01 2014-07-31 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
CA2812845A1 (en) 2010-09-27 2012-04-05 Geistlich Pharma Ag Antimicrobial dental care preparation
HUE034822T2 (en) 2012-06-18 2018-03-28 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents.
WO2015083101A1 (en) * 2013-12-06 2015-06-11 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
CA3000868A1 (en) * 2015-10-07 2017-04-13 Cormedix Inc. Skin-penetrating formulation of taurolidine
KR20180104647A (en) * 2016-01-11 2018-09-21 코르메딕스, 인코포레이티드 Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US20190381058A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Methods and compositions for treating neuroblastoma in a juvenile mammalian body
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
WO2018126133A1 (en) * 2016-12-29 2018-07-05 Cormedix Inc. Skin-penetrating formulation of taurolidine
CN109929804B (en) * 2017-12-15 2020-10-16 天津医科大学肿瘤医院 Human ovarian cancer cell line and preparation method and application thereof
KR20210050543A (en) * 2018-08-28 2021-05-07 코르메딕스, 인코포레이티드 Methods and compositions for treating neuroblastoma in childhood mammalian body
CA3111057A1 (en) * 2018-08-28 2020-02-05 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
KR20210054544A (en) * 2018-08-31 2021-05-13 코르메딕스, 인코포레이티드 Taurolidine Treatment for MYC-expressing Tumors in Mammalian Body
WO2020234829A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Methods and compositions for inhibiting gapdh
WO2020234833A1 (en) 2019-05-22 2020-11-26 Geistlich Pharma Ag Method for treating, preventing, inhibiting or reducing cytokine release

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006138A1 (en) * 1988-11-30 1990-06-14 Ed Geistlich Söhne Ag Für Chemische Industrie Implant for use in bone surgery
WO1992000743A1 (en) * 1990-07-09 1992-01-23 Ed Geistlich Söhne Ag Für Chemische Industrie Use of taurolidine and/or taurultam for the treatment of tumours
WO1994003174A1 (en) * 1992-07-30 1994-02-17 Ed Geistlich Söhne Ag Für Chemische Industrie Treatment of dentoalveolar infections with taurolidine and/or taurultam
WO1998052572A1 (en) * 1997-05-22 1998-11-26 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
EP1066830A2 (en) * 1999-06-04 2001-01-10 Ed. Geistlich Söhne Ag Für Chemische Industrie Uses and compositions for treating primary and secondary tumors of the central nervous system (cns)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1124285A (en) * 1964-10-06 1968-08-21 Geistlich Soehne Ag Novel perhydro-1,2,4-thiadiazine dioxides-(1,1), their preparation and compositionscontaining them
GB1408010A (en) 1972-11-20 1975-10-01 Geistlich Soehne Ag Sulphamoylphenyl-imidazolidinones
GB1557163A (en) * 1975-06-24 1979-12-05 Geistlich Soehne Ag Dental care preparations
US4107305A (en) 1975-08-04 1978-08-15 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Treatment of endotoxaemia
GB1588110A (en) 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4192302A (en) * 1978-09-12 1980-03-11 Boddie Arthur W Hepatic isolation and perfusion circuit assembly
JPS5598170A (en) * 1979-01-18 1980-07-25 Mitsui Toatsu Chem Inc 5-fluorouracil derivative and its preparation
US4337251A (en) 1979-05-09 1982-06-29 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of avoiding and removing adhesions
CA1190855A (en) * 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
GB8328073D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
GB8328074D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compositions
GB8328111D0 (en) * 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
US5206352A (en) * 1986-03-28 1993-04-27 Board Of Trustees Of The University Of Illinois Compositions for clones containing DNA sequences associated with multidrug resistance in human cells
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
US5573771A (en) * 1988-08-19 1996-11-12 Osteomedical Limited Medicinal bone mineral products
US5819748A (en) 1988-11-30 1998-10-13 Ed Geistlich Sohne Ag Fur Chemische Industrie Implant for use in bone surgery
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
EP0521225B1 (en) * 1991-07-04 1994-10-12 Hawe Neos Dental Dr. H. v. Weissenfluh SA Pharmaceutical preparation for treatment of periodontitis, containing clavulanic acid
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
FR2728790B1 (en) * 1994-12-29 1997-01-24 Cird Galderma COMPOSITION MODULATING APOPTOSIS COMPRISING METHONIAL OR ANY FACTOR INFLUENCING THE INTRACELLULAR METHONIAL RATE
US5954687A (en) 1995-04-28 1999-09-21 Medtronic, Inc. Burr hole ring with catheter for use as an injection port
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
GB9600426D0 (en) 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
DE19606897C2 (en) * 1996-02-13 2002-08-29 Geistlich Soehne Ag Means for preventing the spread of tumor cells and the development of trocar metastases in open and laparoscopic surgery of malignant tumors
GB9716219D0 (en) 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6011030A (en) * 1997-09-22 2000-01-04 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating symptoms of microbial infection or sepsis
US5972933A (en) 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006138A1 (en) * 1988-11-30 1990-06-14 Ed Geistlich Söhne Ag Für Chemische Industrie Implant for use in bone surgery
WO1992000743A1 (en) * 1990-07-09 1992-01-23 Ed Geistlich Söhne Ag Für Chemische Industrie Use of taurolidine and/or taurultam for the treatment of tumours
WO1994003174A1 (en) * 1992-07-30 1994-02-17 Ed Geistlich Söhne Ag Für Chemische Industrie Treatment of dentoalveolar infections with taurolidine and/or taurultam
WO1998052572A1 (en) * 1997-05-22 1998-11-26 Oklahoma Medical Research Foundation Use of taurolidine for treatment of leukemias
EP1066830A2 (en) * 1999-06-04 2001-01-10 Ed. Geistlich Söhne Ag Für Chemische Industrie Uses and compositions for treating primary and secondary tumors of the central nervous system (cns)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US8394397B2 (en) 2003-03-28 2013-03-12 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Adhesive antineoplastic compositions

Also Published As

Publication number Publication date
JP2003515557A (en) 2003-05-07
EP2332542B1 (en) 2015-02-11
CA2696185C (en) 2014-09-23
US6429224B1 (en) 2002-08-06
EP1248625A2 (en) 2002-10-16
WO2001039763A2 (en) 2001-06-07
JP5027369B2 (en) 2012-09-19
EP2332542A3 (en) 2011-09-28
US20020111345A1 (en) 2002-08-15
US6703413B2 (en) 2004-03-09
JP6234340B2 (en) 2017-11-22
CA2393159A1 (en) 2001-06-07
CA2393252A1 (en) 2001-06-07
AU2064901A (en) 2001-06-12
DE60030770T2 (en) 2007-09-06
ES2438535T3 (en) 2014-01-17
EP2332542A2 (en) 2011-06-15
ES2531547T3 (en) 2015-03-17
WO2001039762A2 (en) 2001-06-07
EP1246617B1 (en) 2006-09-13
US6964959B2 (en) 2005-11-15
JP2016188244A (en) 2016-11-04
US6995164B2 (en) 2006-02-07
US6521616B2 (en) 2003-02-18
DE60030770D1 (en) 2006-10-26
JP2014198739A (en) 2014-10-23
ATE339207T1 (en) 2006-10-15
AU784538B2 (en) 2006-04-27
AU784539B2 (en) 2006-04-27
US20060135513A1 (en) 2006-06-22
CA2696185A1 (en) 2001-06-07
US20020052366A1 (en) 2002-05-02
CA2393159C (en) 2010-04-20
US20020049200A1 (en) 2002-04-25
AU2065001A (en) 2001-06-12
US20030100551A1 (en) 2003-05-29
JP2003515558A (en) 2003-05-07
JP2012136540A (en) 2012-07-19
EP1246617A2 (en) 2002-10-09
JP5829948B2 (en) 2015-12-09
WO2001039763A3 (en) 2002-07-11
US20030078257A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
ATE319447T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING CLAVULANIC ACID OR DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
IL244727A0 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
CZ309247B6 (en) 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
NO20022014L (en) A solid oral controlled release dosage form containing hydrocodone
WO2001030381A3 (en) Use of csf-1 inhibitors
IL166413A0 (en) Use of and some novel imidazopyridines
MY129473A (en) 3,3-diarylpropylamines, their use and preparation
WO2002036135A3 (en) Compositions for antitumour treatment containing ecteinascidin 743
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE60019436D1 (en) USE OF NICOTINE OR DERIVATIVES AND L-DOPA FOR THE TREATMENT OF NEUROLOGICAL DISEASES, ESPECIALLY MORBUS PARKINSON
SE9901573D0 (en) New compounds
EP1258250A4 (en) Nerve protective drugs
CA2379734A1 (en) Treatment of cancers
SE9901572D0 (en) New compounds
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.
YU25202A (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EE200200549A (en) Split dose therapy with vascular damaging activity
EP1797884A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
MY126998A (en) Substituted pyrroles.
WO2001007029A3 (en) Substituted guanidines and the use thereof
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2393159

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 541495

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 20649/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000983965

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000983965

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000983965

Country of ref document: EP